A New Preclinical Paradigm for Testing Anti-Aging Therapeutics

Area of Science:

• Gerontology
• Pathology
• Pharmacology

Background:

• Traditional mouse life-span studies for anti-aging drugs are costly, time-consuming, and difficult to apply to humans.
• Existing methods are inadequate for testing combination therapies targeting multiple aging factors.
• There is a need for alternative paradigms to evaluate therapeutics aimed at slowing the aging process.

Purpose of the Study:

• To introduce and validate the Geropathology Grading Platform (GGP) as a novel tool for measuring biological aging.
• To establish a standardized method for assessing age-related histopathological lesions in preclinical models.
• To demonstrate the GGP's sensitivity in detecting age-related changes and intervention effects.

Main Methods:

• Developed the Geropathology Grading Platform (GGP) using standardized guidelines for detecting and grading histopathological lesions in aged mouse organs.
• Generated numerical scores for individual lesions, summed to create composite lesion scores (CLS) averaged across multiple mice.
• Utilized preliminary studies to assess CLS changes with mouse age and intervention effects.

Main Results:

• The GGP successfully generated composite lesion scores (CLS) that increased with mouse age in an organ-specific manner.
• Preliminary data indicate that CLS are sensitive to interventions known to extend mouse lifespan.
• The GGP demonstrates potential as a reliable tool for quantifying biological aging in preclinical studies.

Conclusions:

• The Geropathology Grading Platform (GGP) provides a viable, sensitive, and scalable alternative to traditional life-span studies for evaluating anti-aging interventions.
• The GGP can effectively measure biological aging and detect therapeutic effects in aged mice.
• The GGP framework is adaptable for use in various preclinical animal models for aging research.